One To Watch

Merck KGaA

A German science and technology company founded in 1668 — the world's oldest operating pharmaceutical enterprise — with three integrated business sectors in healthcare, life sciences, and electronics, pursuing pipeline renewal across oncology, rare diseases, and neurology with revenues of approximately €21 billion.

Company Overview

Merck KGaA, Darmstadt, Germany is a global science and technology company with operations across three business sectors: Healthcare, Life Sciences, and Electronics. Founded in 1668, it is the world's oldest operating pharmaceutical company. The company generates annual revenues of approximately €21–23 billion and employs around 63,000 people in 66 countries. The Merck family retains majority control with approximately 70% of shares, giving the company a distinctive long-term ownership perspective. In Healthcare, Merck's pharmaceutical franchise spans oncology, rare diseases, immunology, neuroscience, and reproductive health. The Life Sciences division is a leading global provider of tools and materials for biotech and pharma research. The Electronics division serves the global semiconductor industry.

Headquarters and Global Presence

Merck KGaA is headquartered in Darmstadt, Germany, where the company has operated for more than 350 years. The company has commercial and operational presence in 66 countries. In the United States, the company operates as EMD Serono (pharmaceuticals), MilliporeSigma (life sciences), and EMD Electronics. The Healthcare business has significant R&D centres in Darmstadt, Billerica (Massachusetts), and other locations globally. Merck's Life Sciences division, a critical supplier of bioprocess materials, analytical instruments, and laboratory chemicals, operates manufacturing facilities across the United States, Europe, and Asia. The Electronics division is a key supplier to global semiconductor fabrication facilities.

Founding and History

Merck KGaA traces its history to 1668 when Friedrich Jacob Merck, a German apothecary, assumed ownership of the Engel-Apotheke (Angel Pharmacy) in Darmstadt. Emanuel Merck, a descendant of the original founder, took over in 1816 and, using his scientific training, isolated and characterised alkaloids and began manufacturing them at scale from 1827 — launching what is considered the first pharmaceutical manufacturing enterprise. The company commercialised morphine as an early product and expanded into fine chemicals and pharmaceutical manufacturing throughout the 19th and 20th centuries. In 1891, the Merck family established a US subsidiary that was later expropriated during World War I and became the independent Merck & Co. The parent company, Merck KGaA, went public on the Frankfurt Stock Exchange in 1995 and is now listed on the DAX. The Merck family continues to hold approximately 70% of shares.

Therapy Areas and Focus

Merck KGaA's Healthcare division focuses on oncology, rare diseases, immunology, and neuroscience. In oncology, the company markets Bavencio (avelumab), a PD-L1 inhibitor co-developed with Pfizer for urothelial carcinoma and Merkel cell carcinoma, and is advancing DNA damage response inhibitors and ADC programmes. In rare diseases, the acquisition of SpringWorks Therapeutics ($3.4 billion, 2025) added Ogsiveo (nirogacestat) for desmoid tumours and Gomekli (mirdametinib) for NF1-associated plexiform neurofibromas, both FDA-approved. In neuroscience, the company is targeting RNA-based approaches through its partnership with Skyhawk Therapeutics. In reproductive health, Merck markets Gonal-f and other fertility medicines. Mavenclad (cladribine) for multiple sclerosis is a significant neurology asset facing generic pressure.

Technology Platforms and Modalities

Merck KGaA's scientific platforms span small molecules, monoclonal antibodies, antibody-drug conjugates, and RNA-based approaches. In oncology, tuvusertib is a DNA damage response inhibitor (ATR inhibitor) being evaluated in combination with PARP inhibitors and other agents. M9140 is an antibody-drug conjugate targeting CEACAM5, with first-in-human data presented in 2024. TERN-701 (from the Terns Pharmaceuticals acquisition, completed by Merck KGaA), an oral allosteric BCR::ABL1 inhibitor, is in Phase 1/2 for chronic myeloid leukaemia. In neurology, the Skyhawk partnership deploys SkySTAR RNA-targeting small molecule technology. The SpringWorks acquisition added MEK inhibition (mirdametinib) and gamma-secretase inhibition (nirogacestat) as validated oncology mechanisms.

Key Pipeline and Programs

Ogsiveo (nirogacestat, gamma-secretase inhibitor) and Gomekli (mirdametinib, MEK inhibitor), both acquired through the SpringWorks transaction, are commercially active in desmoid tumours and NF1-associated plexiform neurofibromas respectively, representing Merck's expanded rare oncology portfolio. Tuvusertib, an ATR inhibitor, is in Phase 1b/2 trials for DNA damage response-driven cancers, including combinations with PARP inhibitors. M9140 (CEACAM5-targeting ADC) and a second GD2-directed ADC are in early Phase 1 investigation. TERN-701 for chronic myeloid leukaemia has an expanded CARDINAL trial cohort initiated in January 2026. The neurological RNA programme with Skyhawk is in early discovery. Mavenclad continues to be a marketed product despite generic competition concerns.

Key Personnel

Kai Beckmann assumed the role of CEO of Merck KGaA, Darmstadt, Germany effective 1 May 2026, succeeding Belén Garijo (who departed to become CEO of Sanofi). Beckmann, a member of the Executive Board since 2011, led the Electronics business sector through a comprehensive transformation. Danny Bar-Zohar was appointed CEO of the Healthcare business sector, bringing pharmaceutical leadership expertise to guide the pipeline renewal strategy. Jean-Charles Wirth leads the Life Sciences division. David Weinreich joined as Chief Medical Officer of the Healthcare business sector. The Merck family, through a family council arrangement, retains ultimate ownership oversight of the enterprise.

Strategic Partnerships

Merck KGaA's most significant recent transaction was the $3.4 billion acquisition of SpringWorks Therapeutics, completed in 2025, adding two approved rare oncology therapies to its portfolio. The company has a multi-billion dollar partnership with Skyhawk Therapeutics, providing access to the SkySTAR platform for RNA-targeting small molecules in neurology, with up to $2 billion in eligible milestone payments. In March 2026, Merck KGaA exercised its option with Abbisko Therapeutics for worldwide commercialisation rights for tenosynovial giant cell tumour treatment. Bavencio is co-developed and co-commercialised with Pfizer in a longstanding partnership for urothelial and Merkel cell carcinoma. Life Sciences partnerships with bioprocess technology providers and academic institutions underpin the division's role as an innovation enabler for the broader biopharma industry.

FAQ Section

Merck KGaA's central strategic issue is managing the transition to a new CEO in May 2026 while simultaneously addressing generic pressure on Mavenclad in multiple sclerosis, integrating the SpringWorks Therapeutics rare oncology portfolio, and building a next-generation pipeline in oncology and neurology that can sustain the Healthcare business sector's long-term growth.

DDR inhibitors like ATR inhibitor tuvusertib exploit tumour-specific deficiencies in DNA repair pathways, selectively killing cancer cells with pre-existing replication stress while sparing normal tissue; combining ATR inhibition with PARP inhibitors may overcome resistance to either agent alone, addressing a significant unmet need in BRCA-mutated and other homologous recombination-deficient tumours.

Merck KGaA differentiates itself through its unique three-sector model integrating Healthcare, Life Sciences, and Electronics under a single 350-year-old family-controlled enterprise, enabling cross-sector synergies in materials science, bioprocess technology, and semiconductor supply that no other pharmaceutical company possesses, alongside a distinctive long-term ownership philosophy.

Nirogacestat (Ogsiveo) is the first and only FDA-approved gamma-secretase inhibitor for adults with progressing desmoid tumours, a rare and locally aggressive soft tissue tumour with no previously approved systemic therapy; its Phase 3 DeFi trial demonstrated significant progression-free survival improvement, establishing a new standard of care in an orphan oncology indication.

Merck KGaA's Healthcare pipeline is defined by oncology (DDR inhibitors, ADCs targeting CEACAM5 and GD2, and the newly integrated SpringWorks portfolio in rare tumours), neurology (RNA-targeting small molecules via the Skyhawk collaboration and CML through TERN-701), and reproductive health, with the broader group also advancing life sciences tools and semiconductor materials as platform technologies.

Merck KGaA is a mature commercial enterprise generating approximately €21–23 billion in group revenues, with a Healthcare division undergoing active pipeline renewal and portfolio expansion through the SpringWorks acquisition, transitioning from dependence on Mavenclad in MS toward rare oncology, DDR inhibitors, and ADC-based programmes.

Key watchpoints include the strategic priorities and pipeline decisions of new CEO Kai Beckmann from May 2026, Phase 2 data for tuvusertib combinations in DDR-driven cancers, the commercial ramp of Ogsiveo and Gomekli from the SpringWorks portfolio, impact of Mavenclad generic competition on Healthcare revenues, and progress of the TERN-701 programme for chronic myeloid leukaemia.

Want to Update your Company's Profile?